Answers are grounded in this paper and cite their sources.
Araris Biotech, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, developing next-generation antibody-drug conjugates (ADCs), has entered a Research Collaboration and Option to License Agreement with Japanese Chugai Pharmaceutical Co, a subsidiary of Roche, for the development of novel ADCs using Araris' proprietary linker-conjugation technology platform, AraLinQ™, using antibodies against undisclosed targets provided by Chugai.
No takes yet. Share an insight, caveat, or question.
Danielle Garcia (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: